5248042026-04-012026-06-305248042026-04-012026-06-30in-capmkt:OtherExpenses1Member5248042026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524804AUROPHARMANOTLISTEDINE406A01037AUROBINDO PHARMA LIMITEDMain BoardEquity2026-04-012027-03-312026-08-052026-07-27INRMillionsQuarterlyFirst quarterSingle segmentPharmaceutical products2026-08-0516:00:002026-08-0518:30:00Not applicablefalsefalseNo default.2026-04-012026-06-30UnauditedStandalone27995100000241890000030414000000128889000000-4805000002959100000470700000689900000380510000020333200000100808000000100808000002715000000-64000002708600000073722000000000737220000027000007374900000575400000112.7512.750012.7512.75Notes: <br /> 1.The above unaudited standalone financial results of Aurobindo Pharma Limited ("the Company") has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. <br /> 2.The above unaudited standalone financial results of the Company as reviewed by the Audit Committee have been approved by the Board of Directors at its meeting held on August 05, 2026. The results for the quarter ended June 30, 2026 has been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter ended June 30, 2026. <br /> 3.The Company operates in only one reportable segment viz., 'Pharmaceuticals ' in accordance with Ind AS 108, "Operating Segment". <br /> 4.During the year ended March 31, 2026, the Government of India consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Government is in the process of issuing related rules. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations. <br /> The Company assessed the implications of the New Labour Codes and recognized an incremental cost of Rs.173.8 million during the year ended March 31, 2026. <br /> 5.The Board of Directors of Company at their meeting held on April 06, 2026, approved buyback of 5,423,728 fully paid-up equity shares of face value of Re.1 each (representing 0.93% of the total number of equity shares of the Company) for an aggregate value not exceeding Rs.8,000.0 million (buyback size) (excluding transaction cost) at a maximum buyback price of Rs.1,475 per equity share. Upon completion of the buyback, the Company extinguished the equity shares in compliance with applicable rules and regulations. Consequently, the paid-up equity share capital has been reduced by Rs.5.4 million. The aggregate amount paid for buyback is Rs.8,065.3 million including related expenses. <br /> <br /> 6.The Board of Directors of the Company at its meeting held on April 06, 2026 approved the transfer of domestic branded generic pharmaceutical formulations products business on a going concern basis through a Business Transfer Agreement (“BTA”) to Auropharm Limited (previously known as Auro Pharma Limited), a wholly owned subsidiary of the Company on a going concern basis w.e.f April 01, 2026. Accordingly, the net assets of the business have been transferred at the consideration of Rs.1,432.1 Million to Auropharm Limited. <br /> 7.The figures for the quarter ended March 31, 2026, are the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and published year to date figures up to third quarter ended December 31, 2025 and which were subject to limited review by the statutory auditors. <br /> Other Expenses3805100000Re-measurement of defined benefit liability360000036000009000002700000